Eton Pharmaceuticals Enters Asset Purchase Agreement To Acquire Increlex (Mecasermin Injection) From Ipsen; No Terms Disclosed
Eton Pharmaceuticals Enters Asset Purchase Agreement To Acquire Increlex (Mecasermin Injection) From Ipsen; No Terms Disclosed
Increlex is a biologic product used to treat children and adolescents from 2- to 18-years-old who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD) because their bodies do not make enough insulin-like growth factor 1 (IGF-1).
Increlex是一种生物制品，用于治疗2至18岁患有严重原发性胰岛素样生长因子1缺乏症（SPIGFD）的儿童和青少年，因为他们的身体无法产生足够的胰岛素样生长因子1（IGF-1）。
The medicine is approved in 40 territories, including the United States (U.S.) and the European Union (EU). It is estimated that approximately 200 patients in the United States and 900-1,000 patients in Europe live with SPIGFD. Increlex is the only treatment approved by the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) for SPIGFD.
这种药物已获得40个地区的批准，包括美国和欧洲联盟（欧盟）。据估计，美国约有约200名患有SPIGFD的患者，欧洲约有900-1,000名患者。 Increlex是美国食品和药品管理局（FDA）或欧洲药品管理局（EMA）批准用于治疗SPIGFD的唯一治疗方法。
Ipsen reported global sales for Increlex of €17.3 million in 2023.
艾珊报告称，2023年Increlex在全球的销售额为1,730万欧元。
